Subramani Baskar, Ratnavelu Kananathan, Pullai Chithra Ramanathan, Krishnan Kohila, Sugadan Sheela Devi, Deng Xuewen, Hiroshi Terunuma
Nichi-Asia Life Sciences Sdn. Bhd., Petaling Jaya 47810;
Oncol Lett. 2013 May;5(5):1611-1614. doi: 10.3892/ol.2013.1246. Epub 2013 Mar 12.
Current modalities of cancer treatment, including surgery, chemotherapy and radiotherapy, show marginal therapeutic responses in cancer patients. In adoptive immunotherapy, interleukin-2 (IL-2) activated immune cells demonstrated notable results in patients with advanced malignant disease. The present study reports the efficacy and safety of repetitive infusions of autologous immune enhancement therapy (AIET) in a stage IV colonic cancer patient who had already received first-line chemotherapeutic drugs. Peripheral blood was aspirated from the patient. Specifically, natural killer (NK) cells and T-lymphocytes were isolated from the peripheral blood mononuclear cells (PBMCs). These cells were activated and expanded for 14 days and were transfused intravenously to the patient. After six infusions of AIET, the carcinoembryonic antigen (CEA) level was decreased from 901 to 437 U/ml, regression of lesions was noted and there were no adverse reactions during the course of this therapy. Thus, AIET may be a promising anticancer approach to eradicate tumor cells with other conventional therapies.
当前的癌症治疗方式，包括手术、化疗和放疗，在癌症患者中显示出有限的治疗反应。在过继性免疫治疗中，白细胞介素-2（IL-2）激活的免疫细胞在晚期恶性疾病患者中显示出显著效果。本研究报告了重复输注自体免疫增强疗法（AIET）对一名已接受一线化疗药物的IV期结肠癌患者的疗效和安全性。从患者身上采集外周血。具体而言，从外周血单个核细胞（PBMC）中分离出自然杀伤（NK）细胞和T淋巴细胞。这些细胞被激活并扩增14天，然后静脉输注给患者。在六次AIET输注后，癌胚抗原（CEA）水平从901降至437 U/ml，观察到病变消退，并且在该治疗过程中没有不良反应。因此，AIET可能是一种有前景的抗癌方法，可与其他传统疗法联合用于根除肿瘤细胞。
